论文部分内容阅读
紫杉醇自1992年被美国FDA批准上市以来,由于它独特抗癌机理和广谱高效的抗癌活性,其在子宫内膜癌治疗中的作用日益突出,除了单线化疗外,临床上常用的联合化疗有TAP,AT和TP方案。随着科研工作的深入,针对该药不良反应上临床上也有对应的处理措施。
Paclitaxel has been approved by the FDA since its launch in 1992. Due to its unique anti-cancer mechanism and broad-spectrum anti-cancer activity, paclitaxel has become increasingly prominent in the treatment of endometrial cancer. In addition to single-line chemotherapy, paclitaxel is commonly used clinically in combination with chemotherapy TAP, AT and TP programs. With the deepening of scientific research, for the adverse drug reactions on the clinical there are corresponding measures.